logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: healthcare-industry
Load new posts () and activity
Like Reblog Comment
text 2018-10-23 13:37
U.S. Medical Cannabis Market Size, Share, Growth and Trend Analysis, 2014 to 2024

23 October 2018, The U.S. Medical Cannabis Market is expected to be valued at USD 19.48 billion by 2024, driven by its numerous medical benefits particularly by patients suffering from cancer, chronic pain and diabetes. Favorable regulatory environment across numerous states including California and Colorado is expected to fuel the growth of the market over the next few years.

 

Medical Marijuana Regulation and Safety Act implemented in 2015 permits the cultivation and use of cannabis dispensaries at the state and local level which has been one of key drivers to fuel the U.S market. The rising number of states receiving approval to utilize cannabis for consumption in medical cases is expected to be one of the crucial factors to upsurge the demand for medical marijuana over the forecast period.

 

Browse Details of Report @ https://www.hexaresearch.com/research-report/us-medical-cannabis-market

 

Over the past few decades, there have been several controversies surrounding legalization of cannabis for medical purposes; however, increasing signs of medical benefits received from the consumption of cannabis has resulted in the herb being legalized across various states in the nation. The industry is expected to witness significant growth during the forecast period owing to greater consumer acceptance along with an increasing number of companies entering the market.

 

The symptoms and conditions that can be treated by the herb include cancer, arthritis, epilepsy, nausea, pain Alzheimer’s disease, anorexia, AIDS, HIV, glaucoma, cachexia, Crohn’s disease, migraines, and multiple sclerosis. Chronic pain accounted for 46% of the U.S. cannabis medical market share in 2016. The ability of medical marijuana to curb pain is expected to gain popularity among patients diagnosed with chronic illnesses and pain.

 

In 2016, solid edibles segment dominated the U.S market generating revenues worth USD 2.47 billion and is expected to continue dominating the industry over the forecast period. The future product innovation and potential growth are substantial owing to continuous development from the consumption of cannabis infused products owing to their numerous applications including lotions, bath salts, shampoo, lip balm, toothpaste, coffee pods, baked brownies cookies, candy, confectioneries, beverages, vinegar and oils.

 

California is known to be the first state in U.S. that legalized cannabis for medical purpose. In 2016, California recorded the highest revenue generation and is expected to grow at a CAGR of 13% over the projected period. Over the next few years, more number of state governments are expected to legalize cannabis owing to its numerous benefits which will fuel its growth over the projected period.

 

Hexa Research has segmented the U.S. medical cannabis market based on usage, consumption and state:

 

Segmentation by usage, 2014 - 2024 (USD Million)

  • Chronic Pain
  • Arthritis
  • Migraine
  • Cancer
  • Others

 

Segmentation by consumption, 2014 - 2024 (USD Million)

  • Solid Edibles
  • Inhalation
  • Liquid Edibles
  • Topical

 

Segmentation by state, 2014 - 2024 (USD Million)

  • California
  • Colorado
  • Washington
  • Arizona
  • Michigan

 

Key players analyzed

  • American Cannabis
  • Canopy Growth Corporation
  • Greengro Technologies
  • Medical Marijuana Inc.
  • United Cannabis
  • Terra Tech Corp.
  • Mentor Capital, Inc
  • Cannabis Sativa, Inc.
  • GBSciences, Inc.
  • The Green Solution

 

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

Like Reblog Comment
text 2018-10-12 13:52
Visceral Pain Market Size, Shares, Growth and Trend Analysis, 2014 to 2024

12 October 2018, the global Visceral Pain Market is expected to reach USD 14.22 billion by 2024, driven by the increasing geriatric population globally. Increasing prevalence of visceral pain and rising awareness regarding the same is projected to drive market growth over the forecast period.


In 2016, North America held the majority of share in global visceral pain market owing to the increasing healthcare expenditure. Additionally, the high prevalence of Crohn’s and irritable bowel is expected to propel the growth of the market over the projected period.

 

Asia Pacific is expected to be the fastest growing region with the CAGR of 6.2%. The increase in the healthcare infrastructure and presence of a large pool of patients is projected to drive the demand for the visceral pain industry during the forecast period.

 

Analgesic segment dominated the market for the visceral pain with the market share of 60.4%. The major share of the analgesic segment is attributed to the increasing penetration of generic drug. Furthermore, rising healthcare expenditure and an increasing use of opioids for the chronic pain are the key factors attributing to its share.

 

Browse Details of Report @ https://www.hexaresearch.com/research-report/high-heat-foam-market

 

In 2016, Crohn’s disease was the largest indication segment for the visceral pain market contributing to 41.4% of the market share. Increasing occurrences of Crohn’s disease across the globe coupled with the growing drug therapies for the treatment of the disease are the key factors attributing to the major share. Furthermore, increasing awareness about Crohn’s disease is fueling the demand for treatment therapies.

 

Key market players include Pfizer, Johnson & Johnson, Abbvie, Takeda, Allergan, and AstraZeneca. These companies are focusing on R&D for visceral pain therapeutics. These companies are likely to cater their products to patients affected by visceral pain. The growth of the geriatric population is expected to help in augmenting the profits of these companies over the next few years.

 

Growing focus on research and development by pharmaceutical companies and government initiatives are expected to boost the visceral pain industry during the forecast period. The market is projected to witness significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies. Also, factors such as increasing awareness among people regarding visceral pain are further anticipated to propel the market growth.

 

Hexa Research has segmented the global visceral pain market on the basis of therapeutics, indications and region:

 

Segmentation by therapeutics, 2014 - 2024 (USD Million)
• Analgesics
    • Narcotics
    • NSAID
• Pain modifiers
    • Tricyclic Antidepressants
    • Tricyclic Anticonvulsant
• Others


Segmentation by indications, 2014 - 2024 (USD Million)
• Interstitial cystitis
• Crohn’s
• Irritable bowel
• Chronic prostatitis


Segmentation by region, 2014 - 2024 (USD Million)
• North America
• Europe
• Asia Pacific
• Rest of the World (RoW)

 

Key players analyzed:
• Pfizer Inc.
• Allergan 
• Johnson & Johnson
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Mallinkrodt Pharmaceuticals
• AbbVie Inc.
• AstraZeneca

 

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/clinical-diagnostics-industry

Like Reblog Comment
text 2018-10-09 15:04
Probiotics Market Size, Industry Sales and Research Report, 2014 to 2024

9 October 2018, The global Probiotics Market was estimated at over USD 32 billion in 2015. Probiotics are living microorganisms enhance the immune system and help in various urological intestinal disorders.

 

Prebiotics provide health benefits beyond the traditional nutritional function therefore, they are considered as functional foods. The growth of the functional food industry is expected to drive the market in the coming years.

 

Lack of awareness among the consumers about the benefits of probiotics in some regions can hinder market growth. The market is segmented into applications, end-users, and regions.

 

On the basis of applications the market is divided into dietary supplements, food & beverages, and animal feed. Food & beverages accounted for more than 80% of the total market revenue in 2015. This sector consists of bakery, breakfast cereals, dairy, fermented meat, fats & oils, fish & eggs, and soy products.

 

Browse Details of Report @ https://www.hexaresearch.com/research-report/probiotics-market

 

Dietary supplement demand is likely to witness the fastest growth during the forecast period. These supplements are commercially found in forms of capsules, powders, and tablets.

 

End-users include human probiotics and animal probiotics. Human probiotics accounted for over 90% of the total market in 2015. An increase in the standard of living and disposable income in LMEA (Latin America, the Middle East, & Africa) and Asia Pacific can impel market growth in the coming years.

 

Animal feed probiotics is anticipated to grow at a robustly till in the near future. Growing concerns about animal health due to the growth in the meat consumption and recent animal disease outbreaks are key factors that are anticipated to encourage global animal probiotics market.

 

Regions encompass North America, Europe, Asia Pacific, and the Rest of the World (RoW). Asia Pacific probiotics led the global market, holding revenues over 40% in 2015. Prevalence of diabetes in the youth population has promoted the role of probiotics industry in the region.

 

North America is expected to witness moderate growth. The United States of America dominated the regional market. Obesity, digestive disorders, and diabetes, and other growing health concerns can play a major role in the growth the market in this region.

 

Key players of the probiotics market are Danone, Nestle S.A, Danisco, Mother Dairy Fruits & Vegetables Private Limited, and Nestle S.A. Players often adopt strategies like acquisitions, mergers, and strategic alliances to expand their markets.

 

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/nutraceuticals-and-functional-foods-industry

Like Reblog Comment
text 2018-10-08 12:00
Global eClinical Solutions Market Size, Share, Growth and Forecast, 2016 to 2024

8 October 2018, The Global eClinical Solutions Market is anticipated to exceed USD 13 billion by 2024. The major growth driving factors include a rise in the R&D activities by various pharma and biopharma companies, growing application of software solutions in medical trials, rising government funding for promoting clinical research programs, increasing consumer base, and so on. In addition to this, rising outsourcing of medical trials to Contract Research Organization (CROs), growing medical research programs in various Asian countries along with the development of low-cost modules are also projected to boost the market growth.

 

However, high implementation prices, the lack of skilled labor & awareness about clinical data sciences software are likely to hinder the growth of the market in the near future. The global market is divided into products and regions.

 

Browse Details of Report @ https://www.hexaresearch.com/research-report/eclinical-solutions-market

 

The products sector includes Electronic Data Capture (EDC), Electronic Clinical Outcome Assessment (ECOA), Clinical Data Management Systems (CDMS), Randomization and Trial Supply Management (RTSM), Safety Solutions, Clinical Data Integration Platforms, Clinical Trial Management Systems (CTMS), and Electronic Trial Master File (e-TMF). The ECOA sector is projected to experience the maximum growth rate over the forecast period (from 2016 to 2024), while the CDMS and EDC sectors are anticipated to dominate the market through the year 2016.

 

Regionally, the global eClinical solutions market is segregated as Latin America, North America, Asia-Pacific, Europe, and the Middle East & Africa. As of 2016, the North American market is expected to dominate the global market occupying the largest industry share. The major factor for this growth is the growing number of ongoing medical trials in the region. Some other factors include the rising government support for clinical trials, extensive Research & Development activities resulting in the production and launch of innovative products, and the increasing occurrences of lifestyle diseases. The APAC region is also likely to witness a rapid growth over the next few years. The rising participation of developing countries in the clinical trials is said to augment the market growth during the estimated years.

 

The key companies operating in the global eClinical solutions market are Parexel International Corp.; ERT inc.; Oracle Corp.; BioClinica; DataTrak International Inc.; Medidata Solution Inc.; Merge Health Inc.; CRF Health Inc.; OmniComm Systems Inc.; and eClinical Solutions LLC.

 

Related Reports:

Teeth Whitening Products Market - Recommendations from dentist and approvals from the dental associations encourages consumers to utilize lightening products and is anticipated to boost the market over the coming few years.

 

mHealth Market - Smartphone penetration with 3G and 4G networks has multiplied owing to growing urbanization and purchasing power, which is expected to drive mHealth market growth. 

Like Reblog Comment
text 2018-10-05 14:41
Global Tissue Engineering Market Size, Growth and Industry Statistics, 2016 to 2024

5 October 2018, The global Tissue Engineering Market stood at USD 5.5 billion in 2015 and is expected to witness considerable growth even over the forecast period (from 2016 to 2024). Growing needs to bridge the gap between organ demand & supply are expected to drive the industry demand in the near future. Growing popularity in a variety of sectors including urological products, neurology, burn treatment etc. is also anticipated to boost the market growth. Organs developed using this method have high efficiency and durability. Rising applications of this method from surgical treatment of tissues and prosthetics to liver, corneal, cardiac tissue engineering is said to propel the growth from 2016 to 2024. The global market is categorized as applications and regions.

 

The applications include GI & gynecology, cancer, cord blood & cell banking, skin or integumentary, urology, dental, musculoskeletal, spine, orthopedics, neurology, and cardiology & vascular. The orthopedic application sector occupied more than half of the total market share in 2015. The sector is further expected to continue leading the market on account of the increased number of bone implants due to accidents as well as a geriatric population base. The neurology sector is one of the fastest-growing application sectors since it has the wider scope for development. In addition to this, a significant amount of research in the neurology sector is also anticipated to drive the sector growth.

 

Browse Details of Report @ https://www.hexaresearch.com/research-report/tissue-engineering-market

 

Regionally, North America dominated the global tissue engineering market in 2015 accounting for the largest share. It is further projected to continue its dominance even during the forecast period. This can be attributed to the presence of leading players in the region and high financial support for R&D from the government as well as some private organizations. The Asia-Pacific region is expected to be the most lucrative region in the near future. This is mainly because of the existence of immense manpower and highly developed procedures coupled with government funding. The European market is said to register reasonable growth prospects due to the presence of stringent regulatory rules.

 

Major players in the tissue engineering market are acquiring and working in partnerships with small-scale companies so as to influence technology & research advancements and to expand the product portfolio. Some of the key players include Sanofi S. A.; CryoLife Inc.; StemCells Inc.; and BioMimetic Therapeutics Inc.

 

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

More posts
Your Dashboard view:
Need help?